Gapping up
In reaction to strong earnings/guidance: SHOP +18.3%, ENBL +15.2%, CTIC+14%, FOSL +13.2%, SAAS +12.4%, GILT +11.7%, PBPB +11.1%, DIOD +8%,GRMN +7.9%, ATHM +5.9%, SSNI +4.6%, TMUS +4.3%, RLGT +4.2%, ZEN+3.8%, CPB +2.2%, ( raises FY16 guidance, sees FY16 $2.88-2.96 vs $2.82 Capital IQ Consensus Estimate; sees revs $8.00-8.08 bln vs $8.02 bln Capital IQ Consensus Estimate; sees Q2 stronger than anticiptated), FTI+2.2%, BYD +2%, BBW +1.9%, VNO +1.9%
M&A news: TEX +5.4% (Zoomlion affirms commitment to advance the proposed transaction of acquiring Terex for $30/share in cash), SPLS +4.7% (Essendant (ESND) to acquire contracts with minority and woman-owned office supply resellers and their large corporate and other enterprise customers from SPLS)
Select semi conductor related names showing strength: ASX +3.4%, ARMH+2.8%, ASML +1.4%, STM +1.3%, MU +0.9%
Select metals/mining stocks trading higher: MT +3.6%, BBL +2.6%, FCX+1.7%, GG +1.7%, GDX +1.2%, RIO +1.2%
Other news: RGLS +54.9% (announced interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of HCV),ATOS +43.6% (cont momentum higher), FLXN +23.9% (Flexion Therapeutics reports primary endpoint met in pivotal Phase 3 Trial of Zilretta in knee osteoarthritis), KMI +9.2% (Berkshire Hathaway discloses updated portfolio positions in 13F filing with new KMI position), LINE +6.7% (still checking),INO +5.6% (announces that preclinical testing of its synthetic vaccine for the Zika virus induced 'robust and durable' immune responses; plans to initiate phase I human testing before the end of 2016), GALE +5% (Court approved co's settlement regarding derivative litigation), SUNE +4.9% (Luxor Capital discloses new position in SUNE), PSTI +4.7% (cont strength), BTX+3.1% (BioTime and Asterias (AST) sign share transfer agreement and cross-license agreement for Pluripotent stem cell related patents), SCTY +2.8% (Elon Musk files amended 13D showing an increased stake of 22.6% (Prior 21.7%)), TTM +2.6% (cont strength)
Analyst comments: JUNO +3.1% (upgraded to Buy from Neutral at Guggenheim)
In reaction to strong earnings/guidance: SHOP +18.3%, ENBL +15.2%, CTIC+14%, FOSL +13.2%, SAAS +12.4%, GILT +11.7%, PBPB +11.1%, DIOD +8%,GRMN +7.9%, ATHM +5.9%, SSNI +4.6%, TMUS +4.3%, RLGT +4.2%, ZEN+3.8%, CPB +2.2%, ( raises FY16 guidance, sees FY16 $2.88-2.96 vs $2.82 Capital IQ Consensus Estimate; sees revs $8.00-8.08 bln vs $8.02 bln Capital IQ Consensus Estimate; sees Q2 stronger than anticiptated), FTI+2.2%, BYD +2%, BBW +1.9%, VNO +1.9%
M&A news: TEX +5.4% (Zoomlion affirms commitment to advance the proposed transaction of acquiring Terex for $30/share in cash), SPLS +4.7% (Essendant (ESND) to acquire contracts with minority and woman-owned office supply resellers and their large corporate and other enterprise customers from SPLS)
Select semi conductor related names showing strength: ASX +3.4%, ARMH+2.8%, ASML +1.4%, STM +1.3%, MU +0.9%
Select metals/mining stocks trading higher: MT +3.6%, BBL +2.6%, FCX+1.7%, GG +1.7%, GDX +1.2%, RIO +1.2%
Other news: RGLS +54.9% (announced interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of HCV),ATOS +43.6% (cont momentum higher), FLXN +23.9% (Flexion Therapeutics reports primary endpoint met in pivotal Phase 3 Trial of Zilretta in knee osteoarthritis), KMI +9.2% (Berkshire Hathaway discloses updated portfolio positions in 13F filing with new KMI position), LINE +6.7% (still checking),INO +5.6% (announces that preclinical testing of its synthetic vaccine for the Zika virus induced 'robust and durable' immune responses; plans to initiate phase I human testing before the end of 2016), GALE +5% (Court approved co's settlement regarding derivative litigation), SUNE +4.9% (Luxor Capital discloses new position in SUNE), PSTI +4.7% (cont strength), BTX+3.1% (BioTime and Asterias (AST) sign share transfer agreement and cross-license agreement for Pluripotent stem cell related patents), SCTY +2.8% (Elon Musk files amended 13D showing an increased stake of 22.6% (Prior 21.7%)), TTM +2.6% (cont strength)
Analyst comments: JUNO +3.1% (upgraded to Buy from Neutral at Guggenheim)